Endocrine regulation of prostate cancer growth

References

• Kinoshita H, Shi Y, Sandefur C et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res.60, 3623–3630 (2000).
   PubMed Web of Science ®Google Scholar
• Hofman K, Swinnen JV, Verhoeven G, Heyns W. E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem. Biophys. Res. Commun.283, 97–101 (2001).
   PubMed Web of Science ®Google Scholar
• Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res.54, 1566–1573 (1994).
   PubMed Web of Science ®Google Scholar
• Culig Z, Hoffmann J, Erdel M et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer81, 242–251 (1999).
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nature Med.10, 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Fritzer A, Comuzzi B et al. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate66, 413–420 (2006).
   PubMed Web of Science ®Google Scholar
• Eder IE, Culig Z, Ramoner R et al. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy7, 997–1007 (2000).
   PubMed Web of Science ®Google Scholar
• Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res.64, 19–22 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl Acad. Sci. USA99, 7408–7413 (2002).
   PubMed Web of Science ®Google Scholar
• Berger R, Febbo PG, Majunder PK et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res.64, 8867–8875 (2004).
   PubMed Web of Science ®Google Scholar
• Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res.60, 944–949 (2000).
   PubMed Web of Science ®Google Scholar
• Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol. Cell Endocrinol.126, 59–73 (1997).
   PubMed Web of Science ®Google Scholar
• Han G, Buchanan G, Ittmann M et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl Acad. Sci. USA102, 1151–1156 (2005).
   PubMed Web of Science ®Google Scholar
• Hara T, Miyazaki J, Araki H et al. Novel mutations of androgen receptor – a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res.63, 149–153 (2003).
   PubMed Web of Science ®Google Scholar
• Veldscholte J, Ris-Stalpers C, Kuiper GG et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun.17, 534–540 (1990).
   Google Scholar
• Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res.61, 4315–4319 (2001).
   PubMed Web of Science ®Google Scholar
• Agoulnik IU, Vaid A, Bingman WE Jr et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res.65, 7959–7967 (2005).
   PubMed Web of Science ®Google Scholar
• Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CE. Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br. J. Cancer.85, 1928–1936 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Yan J, Luo W et al. SRC-3 is required for prostate cancer proliferation and survival. Cancer Res.65, 7976–7983 (2005).
   PubMed Web of Science ®Google Scholar
• Debes J, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res.63, 7638–7640 (2003).
   PubMed Web of Science ®Google Scholar
• Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates interleukin-6-dependent transactivation of the androgen receptor. Cancer Res.62, 5632–5636 (2002).
   PubMed Web of Science ®Google Scholar
• Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem.277, 7076–7085 (2002).
   PubMed Web of Science ®Google Scholar
• Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res.65, 5965–5973 (2005).
   PubMed Web of Science ®Google Scholar
• Comuzzi B, Nemes C, Schmidt S et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J. Pathol.204, 159–166 (2004).
   PubMed Web of Science ®Google Scholar
• Comuzzi B, Lambrinidis L, Rogatsch H et al. The transciptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am. J. Pathol.162, 233–241 (2003).
   PubMed Web of Science ®Google Scholar
• Halkidou K, Gnanapragasam VJ, Mehta PB et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene22, 2466–2477 (2003).
   PubMed Web of Science ®Google Scholar
• Nishimura K, Ting HJ, Harada Y et al. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res.63, 4888–4894 (2003).
   PubMed Web of Science ®Google Scholar
• Petre-Draviam CE, Cook SL, Burd CJ, Marschall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res.63, 4903–4913 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang XW, Jelovac D et al. W. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc. Natl Acad. Sci. USA102, 9890–9895 (2005).
   PubMed Web of Science ®Google Scholar
• Yoon HG, Wong J. The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. (In Press).
   Google Scholar
• Burd CJ, Petre CE, Morey LM et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc. Natl Acad. Sci. USA103, 2190–2195 (2006).
   PubMed Web of Science ®Google Scholar
• Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med.5, 280–285 (1999).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res.58, 4640–4645 (1998).
   PubMed Web of Science ®Google Scholar
• Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res.7, 1773–1781 (2001).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Rogatsch H, Hittmair A et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol.191, 239–244 (2000).
   PubMed Web of Science ®Google Scholar
• Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer.Am. J. Pathol.159, 2159–2165 (2001).
   PubMed Web of Science ®Google Scholar
• Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem.271, 19900–19907 (1996).
   PubMed Web of Science ®Google Scholar
• Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA96, 5458–5463 (1999).
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Di Domenico M, Castoria G et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res.65, 10585–10593 (2005).
   PubMed Web of Science ®Google Scholar
• Unni E, Sun S, Nan B, McPhaul MJ et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res.64, 7156–7168 (2004).
   PubMed Web of Science ®Google Scholar
• Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology136, 2172–2178 (1995).
   PubMed Web of Science ®Google Scholar
• Wang LG, Ossowski L, Ferrari AC. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res.61, 7544–7551 (2001).
   PubMed Web of Science ®Google Scholar
• Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. AKT-independent protection of prostate cancer from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol. Cell Biol.23, 104–118 (2003).
   PubMed Web of Science ®Google Scholar
• Lin HK, Hu YC, Yang L et al. Suppression vs induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J. Biol. Chem.278, 50902–50907 (2004).
   Web of Science ®Google Scholar
• Wang X, Deng H, Basu I, Zhu L. Induction of androgen receptor-dependent apoptosis in prostate cancer by the retinoblastoma protein. Cancer Res.64, 1377–1385 (2004).
   PubMed Web of Science ®Google Scholar
• Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res.3, 2507–2511 (1997).
   PubMed Web of Science ®Google Scholar
• Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology139, 451–456 (1998).
   PubMed Web of Science ®Google Scholar
• Colombel M, Filleur S, Fournier P et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res.65, 300–308 (2005).
   PubMed Web of Science ®Google Scholar
• Heemers H, Vanderhoydonc F, Roskams T et al. Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol. Cell Endocrinol.205, 21–31 (2003).
   PubMed Web of Science ®Google Scholar
• De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res.63, 3799–3804 (2003).
   PubMed Web of Science ®Google Scholar
• Leav I, Lau KM, Adams JY et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol.159, 79–92 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X, Leav I, Leung YK et al. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol.164, 1883–1886 (2004).
   PubMed Web of Science ®Google Scholar
• Hobisch A, Ramoner R, Fuchs D et al. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin. Cancer Res.7, 2941–2948 (2001).
   PubMed Web of Science ®Google Scholar
• Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao A. C. Stat3 activation in prostatic carcinomas. Prostate51, 241–246 (2002).
   PubMed Web of Science ®Google Scholar
• Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem. Biophys. Res. Commun.257, 609–614 (1999).
   PubMed Web of Science ®Google Scholar
• Steiner H, Godoy-Tundidor S, Rogatsch H et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am. J. Pathol.162, 655–663 (2003).
   PubMed Web of Science ®Google Scholar
• Steiner H, Berger AP, Godoy-Tundidor S et al. Vascular endothelial growth factor autocrine loop is established in prostate cancer cells generated after prolonged treatment with interleukin-6. Eur. J. Cancer40, 1066–1072 (2004).
   PubMed Web of Science ®Google Scholar
• Godoy-Tundidor S, Cavarretta IT, Fuchs D et al. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate64, 209–216 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res.9, 370–376 (2003).
   PubMed Web of Science ®Google Scholar
• Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate42, 1–7 (2000).
   PubMed Web of Science ®Google Scholar
• Mora LB, Buettner R, Seigne J et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res.62, 6659–6666 (2002).
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate42, 186–195 (2000).
   PubMed Web of Science ®Google Scholar
• Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6 and cyclic-AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol. Cell Biol.21, 8471–8482 (2001).
   PubMed Web of Science ®Google Scholar
• Mori S, Murakami-Mori K, Bonavida B. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res.19, 1011–1015 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am. J. Pathol.158, 25–32 (2001).
   PubMed Web of Science ®Google Scholar
• Lee LF, Louie MC, Desai SJ et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene23, 2197–2205 (2004).
   PubMed Web of Science ®Google Scholar
• Signoretti S, Montironi R, Manola J et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst.92, 1918–1925 (2000).
   PubMed Web of Science ®Google Scholar
• Savinaienen KJ, Saramaki OR, Linja MJ et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol.160, 339–345 (2002).
   PubMed Web of Science ®Google Scholar
• Solit DB, Zheng FF, Drobnjak M et al. 17-allylamino-17-demethoxygeeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res.8, 986–993 (2002).
   PubMed Web of Science ®Google Scholar
• Putz T, Culig Z, Eder IE et al. Epidermal growth factor receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res.59, 227–233 (1999).
   PubMed Web of Science ®Google Scholar
• Chen T, Cho RW, Stork PJ, Weber MJ. Elevation of cyclic adenosine 3´5´-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res.59, 213–218 (1999).
   PubMed Web of Science ®Google Scholar
• Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res.63, 1981–1989 (2003).
   PubMed Web of Science ®Google Scholar
• Veeramani S, Igawa T, Yuan TC et al. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene24, 7203–7212 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor protein tyrosine phosphatase α signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene22, 6704–6716 (2003).
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Steele R, Ray RB. c-myc promoter-binding protein (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. J. Biol. Chem.280, 14325–14330 (2005).
   PubMed Web of Science ®Google Scholar
• Mehta PB, Jenkins BL, McCarthy L et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene22, 1381–1389 (2003).
   PubMed Web of Science ®Google Scholar
• Stearns M, Tran J, Francis MK, Zhang H, Sell C. Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res.65, 2085–2088 (2005).
   PubMed Web of Science ®Google Scholar
• Pandini G, Mineo R, Frasca F et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res.65, 1849–1857 (2005).
   PubMed Web of Science ®Google Scholar
• Krueckl SL, Sikes RA, Edlund NM et al. Increased insulin-like growth factor receptor I expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res.64, 8620–8629 (2004).
   PubMed Web of Science ®Google Scholar
• Wu JD, Odman A, Higgins LM et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and andorgan-independent xenograft human prostate tumors. Clin. Cancer Res.11, 3065–3074 (2005).
   PubMed Web of Science ®Google Scholar
• Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P. Blockade of type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF-binding protein-3, and suppresses MMP-2 expression. J. Pathol.202, 50–59 (2004).
   PubMed Web of Science ®Google Scholar
• Kiyama S, Morrison K, Zellweger T et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotoes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res.63, 3575–3584 (2003).
   PubMed Web of Science ®Google Scholar
• Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J.19, 2042–2044 (2005).
   PubMed Web of Science ®Google Scholar
• Liu B, Lee KW, Li H et al. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin. Cancer Res.11, 4851–4856 (2005).
   PubMed Web of Science ®Google Scholar
• Koike H, Ito K, Takezawa Y, Oyama T, Yamanaka H, Suzuki K. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestroli in hormone refractory prostate cancer. Br. J. Cancer92, 1538–1544 (2005).
   PubMed Web of Science ®Google Scholar
• Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res.64, 8715–8722 (2004).
   PubMed Web of Science ®Google Scholar
• Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, Agarwal C. Grape seed extracts inhibits advanced human prostate tumor growth and angiogenesis and upregulate insulin-like growth factor binding protein-3. Int. J. Cancer108, 733–740 (2004).
   PubMed Web of Science ®Google Scholar
• Singh RP, Dhanalakshmi S, Tyagi A, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res.62, 3063–3069 (2002).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kattan MW, Traxel E et al. Association of pre- and postoperative plasma levels of transforming growth factor β(1) and interleukin-6 and its soluble receptor with prostate cancer progression. Clin. Cancer Res.10, 1992–1999 (2004).
   PubMed Web of Science ®Google Scholar
• Edlund S, Lee SY, Grimsby S et al. Interaction between Smad7 and β-catenin: importance for transforming growth factor β-induced apoptosis. Mol. Cell Biol.25, 1475–1488 (2005).
   PubMed Web of Science ®Google Scholar
• Rentsch CA, Cecchini MG, Schwaninger R et al. Differential expression of TGFβ-stimulated clone 22 in normal prostate and prostate cancer. Int. J. Cancer23, 2197–2205 (2006).
   Google Scholar
• San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. Expression of transforming growth factor-β 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int. J. Cancer112, 213–218 (2004).
   PubMed Web of Science ®Google Scholar
• Gerdes MJ, Larsen M, Dang TD, Ressler SJ, Tuxhorn JA, Rowley DR. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-β. Prostate38, 299–307 (2004).
   Google Scholar
• Chipuk JE, Cornelius SC, Pultz N et al. The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J. Biol. Chem.277, 1240–1248 (2002).
   PubMed Web of Science ®Google Scholar
• Hayes SA, Zarnegar M, Sharma M et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res.61, 2112–2118 (2001).
   PubMed Web of Science ®Google Scholar
• Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc. Natl Acad. Sci. USA98, 3018–3023 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-β signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin. Cancer Res.11, 4512–4520 (2005).
   PubMed Web of Science ®Google Scholar
• Partin JV, Anglin IE, Kyprianou N. Quinazoline-based α 1-adrenoreceptor antagonists induce prostate cancer cell apoptosis via TGF-β signalling and I κB α induction. Br. J. Cancer88, 1615–1621 (2003).
   PubMed Web of Science ®Google Scholar
• Cronauer MV, Hittmair A, Eder IE et al. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate31, 223–233 (1997).
   PubMed Web of Science ®Google Scholar
• Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene15, 1115–1120 (1997).
   PubMed Web of Science ®Google Scholar
• Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res.57, 5369–5378 (1997).
   PubMed Web of Science ®Google Scholar
• Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin. Cancer Res.10, 6169–6178 (2004).
   PubMed Web of Science ®Google Scholar
• Cronauer MV, Nessler-Menardi C, Klocker H et al. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br. J. Cancer82, 39–45 (2000).
   PubMed Web of Science ®Google Scholar
• Yan G, Fukabori Y, Nikolaropoulous S, Wang F, McKeehan WL. Heparing-binding keratinocyte growth factor is a candidate stromal-to-epithelial cell andromedin. Mol. Endocrinol.6, 2183–2192 (1992).
   Google Scholar
• Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung H. FGF8 isoform β expression in human prostate cancer. Br. J. Cancer88, 1432–1438 (2003).
   PubMed Web of Science ®Google Scholar
• Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene21, 5069–5080 (2002).
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B, Wang J, Erdem H et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction is decreased in human prostate cancer. Cancer Res.64, 4728–4735 (2004).
   PubMed Web of Science ®Google Scholar
• Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology142, 4795–4805 (2001).
   PubMed Web of Science ®Google Scholar
• Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen independence in the human prostate LNCaP tumor through activation of phosphatidylinositol 3-kinase pathway. Endocrinology141, 2257–2265 (2000).
   PubMed Web of Science ®Google Scholar
• Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3-kinase/PTEN kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res.62, 642–646 (2002).
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons J. W. Androgens stimulate hypoxia-inducible factor activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3´-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res.9, 2416–2425 (2003).
   PubMed Web of Science ®Google Scholar
• Kreisberg JI, Malik SN, Prihoda TJ et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res.64, 5232–5236 (2004).
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Chang C, Nomura M, Matsumoto T. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention. Urol. Int.74, 289–297 (2005).
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathway. Nature Med.10, 594–601 (2004).
   PubMed Web of Science ®Google Scholar
• Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res.64, 6190–6199 (2004).
   PubMed Web of Science ®Google Scholar